AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Achieve Life Sciences Inc (NASDAQ:ACHV)
3.6934 USD
-0.147 3.818%| Previous Close (in USD) | 3.84 |
|---|---|
| Change | -0.147 3.818% |
| 52 W H/L (in USD) | 5.590/3.100 |
| EBITDA (in USD) | -31.037M |
| PE Ratio | -- |
| Volume | 113757 |
| Diluted Eps TTM | -1.12 |
| Total Assets (in USD) | 19.371M |
|---|---|
| Total Liabilities (in USD) | 20.819M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 15.546M |
| Market Cap (in USD) | 156.818 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
1040 West Georgia Street, Vancouver, BC, Canada, V6E 4H1
604-210-2217
Employees: 22
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Richard A. B. Stewart | Exec. Chairman | 1959 |
| 2. | Mr. John A. Bencich M.B.A. | CEO & Director | 1977 |
| 3. | Dr. Cindy Jacobs M.D., Ph.D. | Pres, Chief Medical Officer & Director | 1958 |
| 4. | Mr. Jerry Wan | Principal Accounting Officer | 1982 |
| 5. | Dr. Anthony Clarke | Chief Scientific Officer | 1956 |
| 6. | Ms. Jaime Xinos | Exec. VP of Commercial | NA |
| 7. | Dr. Richard A. B. Stewart | Executive Chairman | 1959 |
| 8. | Dr. Cindy Jacobs M.D., Ph.D. | President, Chief Medical Officer & Director | 1958 |
| 9. | Ms. Jaime Xinos | Executive Vice President of Commercial | NA |
| 10. | Mr. Thomas B. King M.B.A. | Executive Chairman | 1955 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.850 1.219% | 70.245 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.320 1.881% | 71.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+5.035 1.135% | 445 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+13.950 2.725% | 515.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -42.35M | -33.152M | -14.73M | -16.395M | -12.687M |
| Minority Interest | - | - | - | - | - |
| Net Income | -41.875M | -32.902M | -14.661M | -16.141M | -12.687M |
| Selling General Administrative | 10.722M | 9.128M | 7.868M | 6.854M | 6.945M |
| Gross Profit | - | - | - | - | 0M |
| Reconciled Depreciation | 0.236M | 0.25M | 0.255M | 0.254M | 0.282M |
| Ebit | -41.036M | -33.344M | -14.75M | -16.782M | -13.095M |
| Ebitda | -40.8M | -33.094M | -14.495M | -16.528M | -12.813M |
| Depreciation And Amortization | 0.236M | 0.25M | 0.255M | 0.254M | 0.282M |
| Operating Income | -40.8M | -33.094M | -14.75M | -16.528M | -12.813M |
| Other Operating Expenses | 40.8M | 33.094M | 14.75M | 16.528M | 12.813M |
| Interest Expense | 1.789M | 0.017M | 0.069M | 0M | 0M |
| Tax Provision | - | - | - | 0M | 0M |
| Interest Income | 0.199M | 0.017M | 0.069M | 0.17M | 0.171M |
| Net Interest Income | -1.59M | 0.017M | 0.069M | 0.17M | 0.171M |
| Income Tax Expense | -0.475M | -0.25M | -0.069M | -0.254M | -0.126M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 40.8M | 33.094M | 14.75M | 16.528M | 12.813M |
| Cost Of Revenue | - | - | - | - | 0M |
| Total Other Income Expense Net | -1.55M | -0.058M | 0.02M | 0.133M | 0.126M |
| Net Income From Continuing Ops | -42.35M | -33.152M | -14.73M | -16.395M | -12.687M |
| Net Income Applicable To Common Shares | -42.35M | -33.152M | -14.73M | -16.395M | -12.687M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 19.371M | 29.971M | 47.516M | 40.298M | 21.078M |
| Intangible Assets | 1.197M | 1.418M | 1.641M | 1.864M | 2.087M |
| Other Current Assets | 1.325M | 2.454M | 1.419M | 1.122M | 0.67M |
| Total Liab | 20.819M | 21.668M | 19.474M | 3.012M | 3.028M |
| Total Stockholder Equity | -1.448M | 8.303M | 28.042M | 37.286M | 18.05M |
| Other Current Liab | 3.47M | 3.81M | 3.64M | 2.511M | 1.807M |
| Common Stock | 0.09M | 0.087M | 0.079M | 0.076M | 0.041M |
| Capital Stock | 0.09M | 0.087M | 0.079M | 0.076M | 0.041M |
| Retained Earnings | -165.751M | -135.936M | -93.586M | -60.434M | -45.704M |
| Good Will | 1.034M | 1.034M | 1.034M | 1.034M | 1.034M |
| Other Assets | 0M | 0.062M | 0.183M | 0.237M | 0.237M |
| Cash | 15.546M | 24.771M | 43.022M | 35.853M | 16.664M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 20.813M | 5.528M | 4.55M | 2.935M | 2.869M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | 1.185M | -8.573M | -42.949M | -35.684M | -16.302M |
| Short Term Debt | 16.725M | 0.058M | 0.069M | 0.092M | 0.203M |
| Short Long Term Debt | 16.662M | 16.071M | - | - | - |
| Short Long Term Debt Total | 16.731M | 16.198M | 0.073M | 0.169M | 0.362M |
| Other Stockholder Equity | 164.209M | 144.148M | 121.545M | 97.64M | 63.709M |
| Property Plant Equipment | - | 0.127M | 0.064M | 0.042M | 0.057M |
| Total Current Assets | 16.982M | 24.837M | 44.594M | 36.975M | 17.384M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | 0.05M |
| Net Receivables | 0.111M | 0.105M | 0.153M | - | 0.008M |
| Long Term Debt | - | 16.071M | 14.92M | - | - |
| Inventory | - | -2.493M | - | - | -0.008M |
| Accounts Payable | 0.618M | 1.66M | 0.841M | 0.332M | 0.859M |
| Accumulated Other Comprehensive Income | 0.004M | 0.004M | 0.004M | 0.004M | 0.004M |
| Non Currrent Assets Other | -1.168M | 2.559M | 0.168M | 0.237M | 0.237M |
| Non Current Assets Total | 2.389M | 5.134M | 2.922M | 3.323M | 3.694M |
| Capital Lease Obligations | 0.069M | 0.127M | 0.073M | 0.169M | 0.362M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 0M | 0M | -0.017M | 5.089M | -5.089M |
| Total Cashflows From Investing Activities | - | - | -0.017M | 5.036M | -5.125M |
| Total Cash From Financing Activities | 19.295M | 36.61M | 32.68M | 17.325M | 19.757M |
| Net Income | -42.35M | -33.152M | -14.73M | -16.395M | -12.687M |
| Change In Cash | -18.251M | 7.169M | 19.189M | 7.149M | 4.009M |
| Begin Period Cash Flow | 43.072M | 35.903M | 16.714M | 9.565M | 5.556M |
| End Period Cash Flow | 24.821M | 43.072M | 35.903M | 16.714M | 9.565M |
| Total Cash From Operating Activities | -37.549M | -29.44M | -13.474M | -15.216M | -10.623M |
| Depreciation | 0.236M | 0.25M | 0.255M | 0.254M | 0.282M |
| Other Cashflows From Investing Activities | - | - | - | 5.089M | 0.01M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | 0.285M |
| Sale Purchase Of Stock | 18.032M | - | 32.68M | 4.991M | 14.797M |
| Other Cashflows From Financing Activities | 0.083M | 15.267M | 3.183M | 4.199M | 1.324M |
| Capital Expenditures | 0M | 0.017M | 0.017M | 0.053M | 0.046M |
| Change In Working Capital | 0.099M | 1.234M | -0.285M | -0.273M | 0.928M |
| Other Non Cash Items | 1.196M | 0.041M | -19.86M | -0.003M | -7.444M |
| Free Cash Flow | -37.549M | -29.457M | -13.491M | -15.269M | -10.669M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Russell 2000 ETF | 7 months ago | 157131 |
| 2. | Franklin Biotechnology Discovery A | 8 months ago | 2181025 |
| 3. | Franklin Biotechnology Discv A(acc)USD | 7 months ago | 1690170 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 1027821 |
| 5. | iShares Russell 2000 ETF | 6 months ago | 902251 |
| 6. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 629867 |
| 7. | Fidelity Small Cap Index | 8 months ago | 344904 |
| 8. | Simplify Propel Opportunities ETF | 7 months ago | 217845 |
| 9. | iShares Russell 2000 Growth ETF | 6 months ago | 185314 |
| 10. | Fidelity Extended Market Index | 7 months ago | 184460 |
| 11. | State St Russell Sm Cap® Indx SL Cl I | 6 months ago | 152800 |
| 12. | iShares Russell 2000 Value ETF | 6 months ago | 126097 |
| 13. | Schwab Small Cap Index | 7 months ago | 81283 |
| 14. | NT R2000 Index Fund - NL | 8 months ago | 81057 |
| 15. | iShares Micro-Cap ETF | 6 months ago | 80531 |
| 16. | BlackRock Extended Equity Market K | 8 months ago | 74261 |
| 17. | iShares Russell 2000 Small-Cap Idx Instl | 7 months ago | 68670 |
| 18. | NT R2000 Index Fund - DC - NL - 2 | 8 months ago | 64906 |
| 19. | Fidelity Total Market Index | 7 months ago | 60831 |
| 20. | Russell 2000 Index Non-Lendable Fund E | 8 months ago | 57538 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Franklin Resources Inc | 8 months ago | 3871349 |
| 2. | Propel Bio Management LLC | 8 months ago | 2453092 |
| 3. | BlackRock Inc | 11 months ago | 1956510 |
| 4. | Vanguard Group Inc | 8 months ago | 1940388 |
| 5. | Sofinnova Ventures | 8 months ago | 1514032 |
| 6. | Geode Capital Management, LLC | 8 months ago | 749109 |
| 7. | Nantahala Capital Management, LLC | 8 months ago | 654000 |
| 8. | Alyeska Investment Group, L.P. | 8 months ago | 471000 |
| 9. | Shay Capital LLC | 8 months ago | 450000 |
| 10. | State Street Corp | 8 months ago | 431520 |
| 11. | Northern Trust Corp | 8 months ago | 373114 |
| 12. | Long Focus Capital Management, LLC | 8 months ago | 248099 |
| 13. | Goldman Sachs Group Inc | 8 months ago | 234865 |
| 14. | Simplify Asset Management Inc. | 8 months ago | 217845 |
| 15. | LPL Financial Corp | 8 months ago | 191333 |
| 16. | Raymond James & Associates | 8 months ago | 143328 |
| 17. | Morgan Stanley - Brokerage Accounts | 8 months ago | 90661 |
| 18. | Charles Schwab Investment Management Inc | 8 months ago | 89562 |
| 19. | Bank of New York Mellon Corp | 8 months ago | 77217 |
| 20. | CVI Holdings LLC | 11 months ago | 71749 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...